• Christiane G Stäuble and Manfred Blobner.
• Klinik für Anaesthesiologie und Intensivmedizin, Technische Universität München, Klinikum Rechts der Isar, Ismaninger Straße, München, Germany.
• Curr Opin Anaesthesiol. 2020 Aug 1; 33 (4): 490-498.

Purpose Of ReviewThe present review provides a summary of the literature on recent development of new neuromuscular blocking agents and presents clinically well established and new reversal agents.Recent FindingsAnesthesiologists are still waiting for the ideal neuromuscular blocking agent with a succinylcholine-like rapid onset and offset without side effects. Recent drug development led to a new series of neuromuscular compounds, called the chlorofumarates such as gantacurium, CW002, and CW011. These drugs have a promising pharmacodynamic profile; importantly, they can rapidly be reversed by L-cysteine adduction without relevant side effects. In addition, a new spectrum of reversal agents are currently examined in preclinical studies: adamgammadex sodium, a modified γ-cyclodextrin derivate that forms an inactive tight inclusion complex with rocuronium or vecuronium and calabadions, capable of reversing both benzylisoquinolines and steroidal neuromuscular blocking agents.SummaryAlthough the recent advancements in neuromuscular research are very promising, to date, the presented drugs are currently not available for clinical use. Clinical studies will determine the role of these developments in anesthesia practice. Therefore, well established combinations such as rocuronium-sugammadex are popular in clinical practice to offer quick paralysis for intubation and to optimize surgical conditions, while providing a fast neuromuscular recovery at the end of surgery.

11 keywords...

hide…